Venetoclax and Quizartinib in Treating Patients With FLT3-mutated Recurrent or Refractory Acute Myeloid Leukemia
Status:
Recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
This phase Ib/II trial studies the side effects and best dose of venetoclax in combination
with quizartinib and how well they work in treating patients with acute myeloid leukemia that
has come back or does not respond to treatment, and who are FLT3-mutation positive.
Venetoclax and quizartinib may stop the growth of cancer cells by blocking some of the
enzymes needed for cell growth.